Table 4.
p scores for PFS, in the entire cohort and in respective subgroups, derived from individual patient data meta-analysis
| Entire cohort | HBV | HCV | Nonviral | BCLC B | BCLC C | MVI | MVI/EHS | No MVI/EHS | |
|---|---|---|---|---|---|---|---|---|---|
| Anti-PD-(L)1/VEGF Ab | 0.959 | 0.795 | 0.718 | 0.781 | 0.899 | 0.793 | 1.00 | 0.813 | 0.830 |
|
| |||||||||
| Ate-Cab | 0.855 | 0.905 | 0.776 | 0.482 | 0.812 | 0.258 | |||
|
| |||||||||
| Cabozantinib | 0.771 | ||||||||
|
| |||||||||
| T300+D | 0.547 | ||||||||
|
| |||||||||
| Durvalumab | 0.407 | ||||||||
|
| |||||||||
| Nivolumab | 0.551 | ||||||||
|
| |||||||||
| Lenvatinib | 0.840 | 0.581 | 0.558 | 0.564 | 0.707 | 0.617 | 0.682 | ||
|
| |||||||||
| Linifanib | 0.635 | 0.519 | 0.247 | 0.600 | |||||
|
| |||||||||
| Brivanib | 0.327 | ||||||||
|
| |||||||||
| Sunitinib | 0.160 | 0.092 | 0.344 | 0.114 | |||||
|
| |||||||||
| Sor-Erl | 0.158 | ||||||||
|
| |||||||||
| Sorafenib | 0.289 | 0.109 | 0.103 | 0.237 | 0.037 | 0 | 0.386 | 0.012 | 0.129 |
|
| |||||||||
| Placebo | 0 | ||||||||
p scores are a measure of treatment efficacy with higher scores corresponding to higher efficacy. Blanks indicate that HRs for the subgroup were not reported for studies involving that treatment. Anti-PD-(L)1/VEGF Ab, anti-programmed death-1/programmed death-ligand-1 pathway plus vascular endothelial growth receptor monoclonal antibody; Ate-Cab, atezolizumab-cabozantinib; BCLC, Barcelona Clinic Liver Cancer; EHS, extrahepatic spread; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, macrovascular invasion; T300+D, tremelimumab-durvalumab; Sor-Erl, sorafenib-erlotinib.